“Here we provide evidence that the cannabinoid agonist, Delta9-tetrahydrocannabinol Delta9-THC ) enhances quinine palatability and the CB1 antagonist/inverse agonist, AM251, reduces sucrose and quinine palatability using the taste reactivity test, which provides a direct measure of palatability independently of appetitive behavior.”
“Regardless of the post-injection interval, Delta9-THC reduced rejection of quinine.”